Matches in Nanopublications for { ?s ?p "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP131299.RAiRSYro9ioPH39PxZXZd2zvelCqYDRQEIbxlCR7ExZXU130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131299.RAiRSYro9ioPH39PxZXZd2zvelCqYDRQEIbxlCR7ExZXU130_provenance.
- NP131286.RAL2U_cAW805cA4jMLj2b_Qq70VJWUhbq-1oaVNfpg26A130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131286.RAL2U_cAW805cA4jMLj2b_Qq70VJWUhbq-1oaVNfpg26A130_provenance.
- NP194470.RARTtxdIip-i8ActsmYQ7ZkxQ_19nH40AhaajDnyb8tYM130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP194470.RARTtxdIip-i8ActsmYQ7ZkxQ_19nH40AhaajDnyb8tYM130_provenance.
- NP194457.RABcVrWB0s84EJd5WUU1eekGcTjDBft1Q9l7zhAT1iD98130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP194457.RABcVrWB0s84EJd5WUU1eekGcTjDBft1Q9l7zhAT1iD98130_provenance.
- NP227475.RAWN9TxaAtxbcyai_R7s9sUI_9PbLhHquttvgkSAX1ihU130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP227475.RAWN9TxaAtxbcyai_R7s9sUI_9PbLhHquttvgkSAX1ihU130_provenance.
- NP227476.RAkd-nGvpckbiK1-gfTFFdzE8cQ-OhdpRYMGdV3LlcYag130_assertion description "[heterozygous carriers of FVL who experience an episode of venous thromboembolism (VTE) have on average a 40% increased risk of recurrent VTE over non-carriers; risk is lower with heterozygosity of prothrombin G20210A mutation [review]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP227476.RAkd-nGvpckbiK1-gfTFFdzE8cQ-OhdpRYMGdV3LlcYag130_provenance.